PARP1 and neoplasm: Although the radiosensitizing effect of inhibiting PARP was first demonstrated more than 30 years ago, the resurgence of interest in PARPi for sensitizing tumor cells to radiation has been generated by the development of third-generation PAPRi over the past decade that may have clinical utility.